The FDA has granted approval for Boston Scientific's Wallstent, monorail endoprosthesis. Three years have elapsed since results from the BEACH trial summarized outcomes associated with the use of the Wallstent. Since that time devices from Abbot, Cordis, EV3 and the NextStent from Boston Scientific have received approval. The device landscape or carotid stents is crowded. Even in the context of CMS limiting reimbursement to greater than 70%, symptomatic lesions. So although the relative population of treatable patients is static, the available devices has expanded
Positive Results with Abbot's Bioabsorbable Stent
October 13, 2008 -- Abbott (NYSE: ABT) today announced two-year data from 30 patients in its ABSORB clinical trial, demonstrating that its bioabsorbable drug eluting stent successfully treated coronary artery disease and was absorbed into the walls of treated arteries within two years, leaving behind blood vessels that appeared to move and function similar to unstented arteries. Patients who received Abbott's bioabsorbable drug eluting coronary stent and were followed out to two years experienced no stent thrombosis out to two years and no new major adverse cardiac events (MACE) between six months and two years. These results confirmed earlier positive one-year clinical results with Abbott's bioabsorbable drug eluting stent. The results were presented today at the Cardiovascular Research Foundation's 20th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium
Comments